The cancer and inflammatory drug development company will list its Level II ADRs on the NYSE MKT on Tuesday.
Cancer and inflammatory drug development company Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) has obtained approval for listing its Level II American Depository Receipts (ADRs) have been approved for listing on the NYSE MKT, and will begin trading on Tuesday, November 19, 2013 under the ticker symbol "CANF".
"We are excited about the NYSE MKT listing, which should enable us to increase the trading liquidity of our ADRs, broaden our shareholder base, raise our profile in the investment community and provide us a platform to share our value proposition and communicate our strategy with a broader group of investors," said Can-Fite CEO Dr. Pnina Fishman. "Our move to the NYSE MKT reflects Can-Fite's commitment to the US financial markets and our goal to meet the highest standards of disclosure and corporate governance. As our portfolio of indications moves into more advanced stages of clinical development, we believe we will be in a position to pursue additional licensing agreements with some of the world's leading pharmaceutical companies. To support this business development, we are increasing the global visibility of our company through this NYSE MKT listing."
NYSE Euronext EVP Head of Global Listings Scott Cutler said, "As a forward-thinking biotech company with a global reach, Can-Fite is a great example of a growth oriented company that can leverage the NYSE's advanced and innovative market model."
Published by Globes [online], Israel business news - www.globes-online.com - on November 17, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013